Shire Pharmaceuticals Ireland Limited

Chiesi Farmaceutici S.p.a.

Zymenex A/s

Cecilia Weigelt

Jens Fogh

Claes Andersson

Pia Hydén

Stefan Nilsson

Helena Reuterwall

Christer Moller

Kurt Von Figura

Pia Hyden

Christer Môller

Diego Prieto Roces

Meher Irani

Christer MØLLER

The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis.

Process for production and purification of recombinant lysosomal alpha-mannosidase

The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject. A final aspect of the invention provides a method of treating a subject in need thereof, said method comprising administering to said subject a pharmaceutical composition comprising a rhASA and thereby obtaining a reduction in the galactosyl sulphatide levels in target cells within said subject.

Production and purification of recombinant arylsulfatase A

Production and purification of recombinant arylsulftase

Growing community of inventors

Stockholm, Sweden

Cecilia Weigelt